A novel NEXT DPI® dry powder inhaler and its use in asthmatic and COPD population Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Handling and patient preference of dry powder inhalers for asthma and COPD Source: Eur Respir J 2006; 28: Suppl. 50, 210s Year: 2006
The effect of inhaler switching on asthma and COPD patients Source: International Congress 2018 – Respiratory epidemiology: from COPD to factors that associate with lung function and infections Year: 2018
Comparison of two dry powder inhalers containing budesonide in the treatment of asthma in children Source: Eur Respir J 2002; 20: Suppl. 38, 500s Year: 2002
Effect of switching from salmeterol/fluticasone dry powder inhaler to formoterol/fluticasone pressurized metered-dose inhaler in elderly asthma patients Source: International Congress 2016 – Asthma management Year: 2016
The investigation of inhalation continuous duration for dry powder inhalers in asthmatic patients Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Carbon footprint of severe asthma exacerbation management relative to Breezhaler dry powder inhaler Source: Virtual Congress 2021 – Environment and respiratory health Year: 2021
Inhaler treatment options in COPD Source: Eur Respir Rev 2005; 14: 102-108 Year: 2005
Broncho dilator response to salbutamol delivered by metered dose inhaler with spacer versus dry powder inhaler in acute asthma in children Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016
One-year height growth in children with asthma treated with inhaled budesonide delivered from a new dry powder inhaler. Source: Annual Congress 2008 - Clinical aspects of asthma in school-aged children Year: 2008
Formoterol: a new pMDI CFC free formulation. Efficacy of the 12µg dosage versus a dry powder inhaler in moderate to severe asthmatic patients Source: Eur Respir J 2003; 22: Suppl. 45, 284s Year: 2003
Computerized measurements of inhalation ability with a dry powder inhaler in patients with severe COPD Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more Year: 2020
Inhaler choice in primary practice Source: Eur Respir Rev 2005; 14: 117-122 Year: 2005
Long-term preference and ease of use of a novel dry powder inhaler with budesonide in comparison to a conventional inhaler in asthmatic children Source: Eur Respir J 2001; 18: Suppl. 33, 121s Year: 2001
Oral manifestations in asthmatic patients using metered dose inhaler and dry powder inhaler Source: International Congress 2019 – Innovations in primary care assessment and management Year: 2019
Improving inhalation parameters through dry powder inhalers (DPIs) after an acute asthma exacerbation Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Comparison of a formoterol multiple dose dry powder inhaler (MDPI) with a formoterol single dose dry powder inhaler (SDPI) in patients with moderate to severe asthma Source: Eur Respir J 2004; 24: Suppl. 48, 260s Year: 2004
Applicability of dry powder inhalers in children with CF Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016
Inhalation characteristics of asthmatic children (child), adults asthmatics (adult) and chronic obstructive pulmonary disease patients when they inhale through a spiromax dry powder inhaler (DPI) Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
Do asthma patients achieve effective dosing from dry powder inhalers (DPIs)? Source: Eur Respir J 2005; 26: Suppl. 49, 338s Year: 2005